medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2003, Número 4

<< Anterior Siguiente >>

Ann Hepatol 2003; 2 (4)


Hypertransaminasemia and severe hepatic steatosis without inflammation. A case report

Méndez-Sánchez N, Motola-Kuba D, Bahena-Aponte J, Chavez-Tapia N, Pichardo-Bahena R, Uribe M

Idioma: Español
Referencias bibliográficas: 14
Paginas: 183-185
Archivo PDF: 98.25 Kb.


FRAGMENTO

Sin resumen


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Ludwig J, Viggiano RT, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experience with a hitherto unnamed disease. Mayo Clin Proc 1980; 55: 434-438.

  2. Schaffner F, Thaler H. Nonalcoholic fatty liver disease. Prog Liver Dis 1986; 8: 283-298.

  3. Angulo P. Nonalcoholic Fatty Liver Disease. N Engl J Med 2002; 346: 1221-1231.

  4. Reid AE. Nonalcoholic Steatohepatitis. Gastroenterology 2001; 121: 710-723.

  5. Saadeh S, Younossi ZM, Remer EM, Gramlich T, Ong JP, Hurley M, Mullen KD, Cooper JN, Sheridan MJ. The Utility of Radiological Imaging in Nonalcoholic Fatty Liver Disease. Gastroenterology 2002; 123: 745-750.

  6. Joy D, Thava VR, Scott BB. Diagnosis of fatty liver disease: is biopsy necessary? Eur J Gastroenterol Hepatol 2003; 15: 539-543.

  7. Aguilar-Salinas CA, Rojas R, Gomez-Perez FJ, Valles V, Rios-Torres JM, Franco A, Olaiz G, Rull JA, Sepulveda J. Analysis of the agreement between the World Health Organization criteria and the National Cholesterol Education Program-III definition of the metabolic syndrome: results from a population-based survey. Diabetes Care 2003; 26: 1635.

  8. Skelly MM, James PD, Ryder SD. Findings on liver biopsy to investigate abnormal liver function tests in the absence of diagnostic serology. J Hepatol 2001; 35: 195-199.

  9. Dixon JB, Bhathal PS, O´Brien PE. Nonalcoholic Fatty Liver Disease: Predictors of Nonalcoholic Steatohepatitis and Liver Fibrosis in the Severely Obese. Gastroenterology 2001; 121: 91-100.

  10. McNair A. Non-alcoholic steatohepatitis (NASH): Why biopsy? Gut 2002; 51: 898-899.

  11. Day CP. Non-alcoholic steatohepatitis (NASH): where are we now and where are we going? Gut 2002; 50: 585-588.

  12. Sherwood P, Lyburn I, Brown S, Ryder S. How are abnormal results for liver function tests dealt with in primary care? Audit of yield and impact. BMJ 2001; 322: 276-278.

  13. Pratt DS, Kaplan MM. Evaluation of Abnormal Liver-Enzyme Results in Asymptomatic Patients. N Engl J Med 2000; 342: 1266-1271.

  14. Castańo G, Sookoian S. Hepatic focal fatty change in a chronic hepatitis C patient. Ann Hepatol 2002; 1: 147.




2020     |     www.medigraphic.com